The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To assess the association between benzodiazepine and related drug (BZDR) use and risk of Alzheimer's disease (AD) with cumulative consumption and duration of use based models. Method: A nationwide nested case–control study of all Finnish community‐dwelling persons who received clinically verified AD diagnosis in 2005–2011 (N = 70 719) and their matched controls (N = 282 862). AD diagnosis was based on DSM‐IV and NINCDS‐ADRDA criteria. BZDR purchases were extracted from the Prescription Register since 1995. The association between BZDR use and AD was assessed using conditional logistic regression with 5‐year lag time between exposure and outcome. Results: Benzodiazepine and related drug use was associated with modestly increased risk of AD (adjusted OR 1.06, 95% CI 1.04–1.08). A dose–response relationship was observed with both cumulative consumption and duration. Adjustment for other psychotropics removed the cumulative dose–response relationship by attenuating the OR s in the highest dose category. Conclusion: Benzodiazepine and related drug use in general was associated with modestly increased risk of AD. No major differences were observed between different subcategories of BZDR s (i.e. benzodiazepines, Z drugs, short‐/medium‐acting or long‐acting BZDR s). As dose–response relationship abolished after adjustment for other psychotropics, it is possible that the association may partially be due to antidepressants and/or antipsychotics, or concomitant use of these medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger‐Gateau, P., Jacqmin‐Gadda, H., & Dartigues, J. F. (2008) · Annals of Neurology · doi:10.1002/ana.21509 · Cited by 737
Late-life depression, mild cognitive impairment, and dementia
Richard, E., Reitz, C., Honig, L. H., Schupf, N., Tang, M. X., Manly, J. J., Mayeux, R., Devanand, D., & Luchsinger, J. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.603 · Cited by 389 · cited 1×
“BZDRs are used to treat prodromal or neuropsychiatric symptoms of dementia/AD such as anxiety and insomnia.[14-16] Because AD has long latency period, prodromal symptoms can arise years before diagnosis of AD.”
BackgroundCognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312 · cited 1×
“Short-term negative effects on memory and cognition are well known.[9-12] Thus, their long-term use has been hypothesized to hasten cognitive decline and increase dementia risk.”
BackgroundGray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 2×
“This result is in line with one previous study (17), which found risk for dementia with two lowest cumulative consumption categories but not with the highest consumption category.”
ResultFourrier, A., Letenneur, L., Dartigues, J., Moore, N., & Bégaud, B. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100326 · Cited by 158 · cited 2×
“This is worrying because BZDRs are commonly used among old persons[1-5], and despite recommendations[7], the use is often longterm[8].”
BackgroundNeuropsychiatric symptoms in the prodromal stages of dementia
Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., de Souza, L. C., & Forlenza, O. V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000050 · Cited by 90 · cited 1×
“BZDRs are used to treat prodromal or neuropsychiatric symptoms of dementia/AD such as anxiety and insomnia.[14-16] Because AD has long latency period, prodromal symptoms can arise years before diagnosis of AD.”
BackgroundAlprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing
Kroboth, P. D., McAuley, J. W., & Smith, R. B. (1990) · Psychopharmacology · doi:10.1007/bf02243999 · Cited by 35 · cited 1×
“(18), with the exception of alprazolam that was classified as long-acting, because of its increased half-life in old adults (30).”
Background
Cited by
The glymphatic system: implications for drugs for central nervous system diseases
Lohela, T. J., Lilius, T. O., & Nedergaard, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00500-9 · Cited by 254
Dyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.006 · Cited by 39
Cortes-Flores, H., Torrandell-Haro, G., & Brinton, R. D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1358568 · Cited by 12
Should benzodiazepines be avoided?
Jørgensen, M. B., & Osler, M. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12943 · Cited by 6
Metadata
- Authors
- Tapiainen, V., Taipale, H., Tanskanen, A., Tiihonen, J., Hartikainen, S., & Tolppanen, A. ‐.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2018-05-31
- Volume
- 138
- Issue
- 2
- Pages
- 91-100
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2807313810
- Cited by
- 53
- References
- 8
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.